We evaluated the efficacy of sevelamer hydrochloride (sevelamer) in hemodialysis patients. Twenty patients (male 15, female 5) with a serum phosphate (Pi) level above 5.5mg/dL and corrected serum calcium (Ca) above 9.5mg/dL on chronic maintenance hemodialysis (more than 4 hours, 3 times/week) for over 1 year were enrolled. Calcium carbonate and other phosphate binders were all discontinued, and sevelamer was given for eight weeks. The dosage was determined in accordance with the appended paper, considering side effects such as digestive system disorder.
During the 12-week study period that included 4 weeks before the change in phosphate binder, hemodialysis conditions and dosages of medicines that can effect calcium and phosphate metabolism, such as vitamin D analogues, were left unchanged. During the study period, 4 patients dropped out due to side effects. We analysed blood chemical data consisting of serum phosphate (Pi), calcium (Ca), ALP, intact PTH (i-PTH), total cholesterol (TC), LDL-cholesterol (LDL-C), HDL-cholesterol (HDL-C), and HCO
3- in 16 patients who completed 8 weeks of therapy. There were no significant changes observed in Pi, or Ca×Pi product, while HDL-C, Ca, TC, LDL-C, and HCO
3- all decreased significantly and ALP and HCO
3- both increased significantly.
Sevelamer alone can control serum Pi as well as calcium carbonate can, but in some cases, side effects prevented administration of a sufficient dose of sevelamer. Controlling side effects in order to administer an adequate dose of sevelamer, and how to use in combination with other phosphate binders are problems that remain to be resolved.
View full abstract